Browse the evidence

Bariatric surgery (specifically Roux-en-Y gastric bypass) provides the greatest long-term weight loss and diabetes remission rates compared to other surgical and non-surgical interventions.

For severe obesity (BMI >40 or >35 with health issues), surgery is the most effective long-term solution. Roux-en-Y bypass offers the best results for weight loss and diabetes remission. It requires lifelong vitamin supplements and lifestyle changes, but offers the highest chance of sustained health improvement.

GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists (GIP/GLP-1 RAs) significantly reduce body weight and improve metabolic health in individuals with obesity and type 2 diabetes.

If you have obesity or type 2 diabetes, GLP-1 and GIP/GLP-1 medications (like semaglutide or tirzepatide) are highly effective for weight loss and improving metabolic health. These drugs work by mimicking gut hormones to reduce appetite and improve insulin sensitivity. To get the best results and minimize side effects, start with a low dose and increase it slowly. It is also crucial to combine medication with lifestyle changes, specifically focusing on strength training and eating enough protein to protect your muscles from being lost along with fat.

Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) provide greater weight reduction and better metabolic control compared to GLP-1 receptor mono-agonists.

If you are not achieving sufficient weight loss with a GLP-1 medication like semaglutide, switching to a dual GIP/GLP-1 agonist like tirzepatide may offer greater benefits. Clinical trials show that tirzepatide can lead to even more significant weight loss compared to existing GLP-1 drugs. This makes it a strong option for those who need more aggressive treatment.

Tirzepatide significantly reduces apnea-hypopnea index (AHI) and resolves obstructive sleep apnea (OSA) in obese patients, with approximately 50% achieving resolution after 52 weeks of treatment.

If you have obesity and OSA, tirzepatide (10-15mg weekly) can significantly reduce your apnea severity and may even resolve OSA in half of users after one year. It is not a quick fix; it takes time to lose weight. For severe cases, it should be used alongside CPAP initially, with the goal of potentially reducing CPAP dependence as weight loss occurs. Long-term use is likely necessary to maintain benefits.

Creatine monohydrate (CM) is the gold standard for efficacy, safety, and cost-effectiveness, while approximately 88% of alternative creatine products on the market have limited to no scientific evidence supporting their bioavailability, efficacy, or safety.

When buying creatine, look for Creatine Monohydrate. It is the most studied, safest, and cheapest option. Be wary of 'alternative' forms (like HCl, Ethyl Ester, etc.) as 88% of them lack scientific evidence for safety or effectiveness. Additionally, only 8% of products are third-party certified, so verify certifications if purity is a concern.

GLP-1 receptor agonists (specifically semaglutide and tirzepatide) significantly improve cardiovascular outcomes, symptoms, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, primarily through substantial weight loss and metabolic improvement.

If you have HFpEF and are obese, GLP-1 medications like semaglutide or tirzepatide are now proven to help your heart, reduce symptoms, and improve your quality of life. The key is that this is intentional weight loss, which is different from the involuntary weight loss seen in advanced heart failure. Discuss these options with your cardiologist, as they can significantly reduce your risk of hospitalization and cardiovascular death.

GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide produce clinically significant weight loss (15-22.5%) and cardiovascular risk reduction, serving as a scalable pharmacological adjunct to lifestyle interventions.

GLP-1 RAs like semaglutide and tirzepatide are highly effective medications for weight loss, producing 15-22% body weight loss in clinical trials. They work by mimicking gut hormones to reduce appetite and improve metabolic health. They are not a 'magic bullet' but a tool that works best when combined with dietary changes, physical activity, and psychological support. Common side effects like nausea are usually temporary and manageable. These drugs are particularly useful for those who have struggled with long-term weight maintenance through lifestyle changes alone.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce significantly greater weight loss (10-20%+) compared to other anti-obesity medications (3-7%) and placebo.

If lifestyle changes are not enough, GLP-1 medications like semaglutide (Wegovy) or tirzepatide (Mounjaro) offer the highest weight loss potential (10-20%). These are injectable medications typically used when BMI is >30 (or >27 with comorbidities). They work by reducing appetite and slowing digestion. Consult a physician to see if you qualify.

Dietary patterns significantly shape the gut microbiome, with fiber-rich diets increasing diversity and beneficial bacteria, while high-fat diets decrease diversity and promote pro-inflammatory species.

Prioritize fiber-rich foods (vegetables, fruits, whole grains) to support microbial diversity and beneficial bacteria. Limit high-fat, processed foods which reduce diversity and promote inflammation.

Significant weight loss (typically >10%) induced by intensive lifestyle interventions (very low-calorie diets) or metabolic bariatric surgery can induce remission of type 2 diabetes (HbA1c < 6.5% without medication), primarily by reversing ectopic fat accumulation in the pancreas and liver.

If you have recently been diagnosed with Type 2 diabetes, prioritize significant weight loss immediately. Clinical trials show that losing a substantial amount of weight (often via structured, low-calorie diet programs) can put your blood sugar into remission (normal levels without medication), especially if you act within the first few years of diagnosis. This reverses the fat accumulation in your pancreas and liver that is driving the disease.

Pharmacological treatment with Semaglutide (2.4 mg) achieves clinically relevant weight loss (~16%) regardless of the intensity of concurrent lifestyle interventions.

Take Semaglutide 2.4 mg once weekly. While you should still try to eat slightly less and move more, do not expect these lifestyle changes to drive your weight loss. The medication does the heavy lifting by correcting your biology. Expect ~16% weight loss over 68 weeks.

Intensive lifestyle intervention (≥150 min/week moderate exercise and 500-1000 kcal/day caloric deficit) significantly reduces the incidence of new-onset type 2 diabetes compared to placebo, with benefits persisting for at least 21 years.

To prevent type 2 diabetes, aim for 150 minutes of moderate exercise per week and eat 500-1000 calories less than you burn daily. This combination helps you lose 7% of your body weight. The benefits last for decades, reducing your risk of diabetes and related complications like heart disease and kidney issues. Start with small, sustainable changes to diet and activity.

GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 agonists (e.g., tirzepatide) provide superior glycemic control and significant body weight reduction compared to standard therapies, establishing them as cornerstone treatments for type 2 diabetes and obesity.

If you have Type 2 Diabetes or Obesity, GLP-1 and dual-agonist medications are now considered cornerstone treatments that offer better blood sugar control and weight loss than older therapies, especially if you have heart or kidney risks. These drugs work by mimicking gut hormones to increase insulin, slow digestion, and reduce appetite. While they can cause stomach issues, starting with a low dose and slowly increasing it helps your body adjust. Oral versions are available for some drugs, removing the need for injections for those who prefer it.

Carbohydrate-restricted diets (≤45% energy) significantly improve cardiovascular health by reducing triglycerides, blood pressure, and inflammatory markers, despite modest increases in LDL and total cholesterol.

Adopting a diet with less than 45% of calories from carbs improves heart health markers like blood pressure and triglycerides. Even if your LDL cholesterol rises slightly, your overall cardiovascular risk likely decreases because your triglycerides drop, inflammation goes down, and your cholesterol ratios improve. This is especially true if you replace carbs with a mix of fats and proteins.

Carbohydrate-restricted diets lead to significant reductions in body weight, body fat percentage, and visceral adipose tissue compared to higher-carbohydrate diets.

Cutting carbs to under 45% of your calories is an effective strategy for losing body fat and visceral fat. You will likely lose some weight and body fat percentage, especially if you are overweight. Be aware that you might lose some lean muscle mass along with the fat, so monitoring your strength and considering resistance training is advisable.

Second-generation obesity medications (semaglutide 2.4 mg and tirzepatide) achieve clinically significant weight loss (≥15% body weight) and treat or prevent obesity-related complications, establishing a complications-centric approach to care.

If you have obesity, especially with complications like diabetes or heart disease, second-generation medications like semaglutide or tirzepatide are now available that can help you lose 15% or more of your body weight. This level of weight loss is significant enough to improve or prevent many serious health issues. The main barrier is often cost and insurance coverage, so advocate for your access to these treatments as a medical necessity.

Weekly subcutaneous semaglutide (2.4 mg) significantly reduces body weight and major adverse cardiovascular events in non-diabetic patients with obesity and established cardiovascular disease.

If you have obesity and existing heart disease, ask your doctor about weekly semaglutide injections (2.4 mg). This treatment has been shown to significantly reduce your body weight and lower your risk of heart attacks, strokes, and death, offering strong protection for your heart.

Semaglutide 2.4 mg subcutaneous once weekly significantly reduces body weight and improves cardiovascular risk factors in obese or overweight adults with or without type 2 diabetes.

Semaglutide 2.4 mg injected once weekly, combined with a low-calorie diet and exercise, is a highly effective treatment for weight loss and cardiovascular risk reduction in obese or overweight adults. You must commit to long-term use, as stopping the medication leads to weight regain. Start with a lower dose to minimize stomach side effects, which usually improve over time.

Concomitant administration of ixekizumab (IL-17A inhibitor) and tirzepatide (dual GIP/GLP-1 receptor agonist) achieves significantly greater disease control and weight loss in adults with psoriatic arthritis (PsA) and overweight/obesity compared to ixekizumab monotherapy.

For PsA patients who are overweight or obese, adding tirzepatide to ixekizumab therapy offers a dual benefit: significantly better joint symptom control and substantial weight loss, compared to using ixekizumab alone. This combination addresses both the inflammatory and metabolic aspects of the disease, leading to improved physical function and quality of life, with a safety profile consistent with the individual drugs.

Short sleep duration (less than 5 hours per night) is significantly associated with an increased risk of obesity, with an odds ratio of 1.89 in children and 1.55 in adults.

Aim for 7-8 hours of sleep per night. Sleeping less than 5 hours significantly increases your risk of obesity. Prioritize sleep as a key component of your metabolic health strategy.

Tirzepatide, a dual GLP-1 and GIP receptor agonist, produces superior weight loss (up to 20.9%) and visceral fat reduction compared to other anti-obesity medications.

Tirzepatide is currently the most effective pharmacological tool for significant weight loss, capable of reducing body weight by over 20% in clinical trials. It works by mimicking two gut hormones (GLP-1 and GIP) to reduce appetite and fat storage. While highly effective, it requires weekly injections and careful monitoring for gastrointestinal side effects like nausea.

Semaglutide 2.4 mg administered weekly results in a mean weight loss of 14.9% over 68 weeks, significantly outperforming placebo.

Semaglutide 2.4 mg, taken as a weekly injection, is a highly effective treatment for obesity, leading to an average 14.9% weight loss over 68 weeks. It works by mimicking the GLP-1 hormone to increase satiety and reduce appetite. Common side effects include gastrointestinal issues like nausea and diarrhea.

Bariatric surgery (Roux-en-Y gastric bypass and sleeve gastrectomy) is recommended for individuals with BMI > 35 kg/m² regardless of comorbidities, and for those with BMI 30-34.9 kg/m² and metabolic diseases.

Bariatric surgery is now recommended for individuals with a BMI over 35, even without other health issues, and for those with a BMI of 30-34.9 who have metabolic diseases. Procedures like Roux-en-Y gastric bypass and sleeve gastrectomy provide substantial long-term weight loss and improve quality of life.

Obesity is a major independent risk factor for the development of coronary artery disease, heart failure, atrial fibrillation, and sudden cardiac death, with risk increasing linearly with BMI and visceral adiposity.

If you have excess body fat, especially around your midsection, your risk for heart disease, heart failure, and arrhythmias increases significantly, even if your blood pressure and cholesterol are normal. Do not rely on BMI alone; ask your doctor about assessing visceral fat or using waist circumference, as these are better predictors of heart risk.